Gabory (2009). “H19 acts as a trans regulator of the imprinted gene network controlling growth in mice”. Development136 (20): 3413–3421. doi:10.1242/dev.036061. PMID19762426.
“Establishment of functional imprinting of the H19 gene in human developing placentae”. Nat. Genet.10 (3): 318–324. (July 1995). doi:10.1038/ng0795-318. PMID7670470.
“The effect of retinoic acid on the activation of the human H19 promoter by a 3' downstream region”. FEBS Lett.432 (3): 123–127. (August 1998). doi:10.1016/S0014-5793(98)00841-2. PMID9720909.
“H19 mRNA-like noncoding RNA promotes breast cancer cell proliferation through positive control by E2F1”. J. Biol. Chem.280 (33): 29625–29636. (August 2005). doi:10.1074/jbc.M504033200. PMID15985428.
“Ectopic expression of the H19 gene in mice causes prenatal lethality”. Genes Dev.5 (6): 1092–1101. (June 1991). doi:10.1101/gad.5.6.1092. PMID2044956.
“An enhancer deletion affects both H19 and Igf2 expression”. Genes Dev.9 (17): 2079–2089. (September 1995). doi:10.1101/gad.9.17.2079. PMID7544754.
“Association of IGF2 and H19 imprinting with choriocarcinoma development”. Cancer Genet. Cytogenet.93 (1): 39–47. (January 1997). doi:10.1016/S0165-4608(96)00221-X. PMID9062579.
“Characterization of human and mouse H19 regulatory sequences”. Mol. Biol. Rep.27 (3): 157–165. (September 2000). doi:10.1023/A:1007139713781. PMID11254105.
“Steroid hormones modulate H19 gene expression in both mammary gland and uterus”. Oncogene18 (31): 4460–4473. (August 1999). doi:10.1038/sj.onc.1202819. PMID10442637.
“Polyploidization of murine mesenchymal cells is associated with suppression of the long noncoding RNA H19 and reduced tumorigenicity”. Cancer Research72 (24): 6403–6413. (December 2012). doi:10.1158/0008-5472.CAN-12-1155. PMID23047867.
“Association of H19 promoter methylation with the expression of H19 and IGF-II genes in adrenocortical tumors”. J. Clin. Endocrinol. Metab.87 (3): 1170–1176. (March 2002). doi:10.1210/jc.87.3.1170. PMID11889182.
“Overexpression of an ectopic H19 gene enhances the tumorigenic properties of breast cancer cells”. Carcinogenesis23 (11): 1885–1895. (November 2002). doi:10.1093/carcin/23.11.1885. PMID12419837.
“The c-Myc oncogene directly induces the H19 noncoding RNA by allele-specific binding to potentiate tumorigenesis”. Cancer Res.66 (10): 5330–5337. (May 2006). doi:10.1158/0008-5472.CAN-06-0037. PMID16707459.
“The expression of the imprinted H19 and IGF-2 genes in human bladder carcinoma”. FEBS Lett.374 (1): 57–61. (October 1995). doi:10.1016/0014-5793(95)01074-O. PMID7589512.
“Expression of the imprinted H19 oncofetal RNA in epithelial ovarian cancer”. Eur. J. Obstet. Gynecol. Reprod. Biol.85 (1): 7–11. (July 1999). doi:10.1016/S0301-2115(98)00275-9. PMID10428315.
“Frequent loss of imprinting at the IGF2 and H19 genes in head and neck squamous carcinoma”. Oncogene18 (50): 7063–7069. (November 1999). doi:10.1038/sj.onc.1203192. PMID10597307.
“A prognostic multigene classifier for squamous cell carcinomas of the larynx”. Cancer Letters307 (1): 37–46. (August 2011). doi:10.1016/j.canlet.2011.03.013. PMID21481529.
“Thioredoxin post-transcriptional regulation by H19 provides a new function to mRNA-like non-coding RNA”. Oncogene21 (10): 1625–1631. (February 2002). doi:10.1038/sj.onc.1205233. PMID11896592.
“Biallelic expression of the H19 and IGF2 genes in hepatocellular carcinoma”. Cancer Lett.119 (2): 143–148. (November 1997). doi:10.1016/S0304-3835(97)00264-4. PMID9570364.
“Phase I/II Marker Lesion Study of Intravesical BC-819 DNA Plasmid in H19 Over Expressing Superficial Bladder Cancer Refractory to Bacillus Calmette-Guerin”. The Journal of Urology180 (6): 2379–2383. (December 2008). doi:10.1016/j.juro.2008.08.006. ISSN0022-5347. PMID18950807.
“Breast Cell Line MCF-7”. Cancer Biology - Breast Cancer Cell Line Database. University of Texas M. D. Anderson Cancer Center. 2008年6月6日閲覧。
nih.gov
pubmed.ncbi.nlm.nih.gov
Gabory (2009). “H19 acts as a trans regulator of the imprinted gene network controlling growth in mice”. Development136 (20): 3413–3421. doi:10.1242/dev.036061. PMID19762426.
“Establishment of functional imprinting of the H19 gene in human developing placentae”. Nat. Genet.10 (3): 318–324. (July 1995). doi:10.1038/ng0795-318. PMID7670470.
“The effect of retinoic acid on the activation of the human H19 promoter by a 3' downstream region”. FEBS Lett.432 (3): 123–127. (August 1998). doi:10.1016/S0014-5793(98)00841-2. PMID9720909.
“H19 mRNA-like noncoding RNA promotes breast cancer cell proliferation through positive control by E2F1”. J. Biol. Chem.280 (33): 29625–29636. (August 2005). doi:10.1074/jbc.M504033200. PMID15985428.
“Ectopic expression of the H19 gene in mice causes prenatal lethality”. Genes Dev.5 (6): 1092–1101. (June 1991). doi:10.1101/gad.5.6.1092. PMID2044956.
“An enhancer deletion affects both H19 and Igf2 expression”. Genes Dev.9 (17): 2079–2089. (September 1995). doi:10.1101/gad.9.17.2079. PMID7544754.
“Association of IGF2 and H19 imprinting with choriocarcinoma development”. Cancer Genet. Cytogenet.93 (1): 39–47. (January 1997). doi:10.1016/S0165-4608(96)00221-X. PMID9062579.
“Characterization of human and mouse H19 regulatory sequences”. Mol. Biol. Rep.27 (3): 157–165. (September 2000). doi:10.1023/A:1007139713781. PMID11254105.
“Steroid hormones modulate H19 gene expression in both mammary gland and uterus”. Oncogene18 (31): 4460–4473. (August 1999). doi:10.1038/sj.onc.1202819. PMID10442637.
“Polyploidization of murine mesenchymal cells is associated with suppression of the long noncoding RNA H19 and reduced tumorigenicity”. Cancer Research72 (24): 6403–6413. (December 2012). doi:10.1158/0008-5472.CAN-12-1155. PMID23047867.
“Association of H19 promoter methylation with the expression of H19 and IGF-II genes in adrenocortical tumors”. J. Clin. Endocrinol. Metab.87 (3): 1170–1176. (March 2002). doi:10.1210/jc.87.3.1170. PMID11889182.
“Overexpression of an ectopic H19 gene enhances the tumorigenic properties of breast cancer cells”. Carcinogenesis23 (11): 1885–1895. (November 2002). doi:10.1093/carcin/23.11.1885. PMID12419837.
“The c-Myc oncogene directly induces the H19 noncoding RNA by allele-specific binding to potentiate tumorigenesis”. Cancer Res.66 (10): 5330–5337. (May 2006). doi:10.1158/0008-5472.CAN-06-0037. PMID16707459.
“The expression of the imprinted H19 and IGF-2 genes in human bladder carcinoma”. FEBS Lett.374 (1): 57–61. (October 1995). doi:10.1016/0014-5793(95)01074-O. PMID7589512.
“Expression of the imprinted H19 oncofetal RNA in epithelial ovarian cancer”. Eur. J. Obstet. Gynecol. Reprod. Biol.85 (1): 7–11. (July 1999). doi:10.1016/S0301-2115(98)00275-9. PMID10428315.
“Frequent loss of imprinting at the IGF2 and H19 genes in head and neck squamous carcinoma”. Oncogene18 (50): 7063–7069. (November 1999). doi:10.1038/sj.onc.1203192. PMID10597307.
“A prognostic multigene classifier for squamous cell carcinomas of the larynx”. Cancer Letters307 (1): 37–46. (August 2011). doi:10.1016/j.canlet.2011.03.013. PMID21481529.
“Thioredoxin post-transcriptional regulation by H19 provides a new function to mRNA-like non-coding RNA”. Oncogene21 (10): 1625–1631. (February 2002). doi:10.1038/sj.onc.1205233. PMID11896592.
“Biallelic expression of the H19 and IGF2 genes in hepatocellular carcinoma”. Cancer Lett.119 (2): 143–148. (November 1997). doi:10.1016/S0304-3835(97)00264-4. PMID9570364.
“Phase I/II Marker Lesion Study of Intravesical BC-819 DNA Plasmid in H19 Over Expressing Superficial Bladder Cancer Refractory to Bacillus Calmette-Guerin”. The Journal of Urology180 (6): 2379–2383. (December 2008). doi:10.1016/j.juro.2008.08.006. ISSN0022-5347. PMID18950807.
“Phase I/II Marker Lesion Study of Intravesical BC-819 DNA Plasmid in H19 Over Expressing Superficial Bladder Cancer Refractory to Bacillus Calmette-Guerin”. The Journal of Urology180 (6): 2379–2383. (December 2008). doi:10.1016/j.juro.2008.08.006. ISSN0022-5347. PMID18950807.